Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Sargramostim | |
| Synonyms |
Sagramostim Sargramostatin SARGRAMOSTIM 23-L-Leucinecolony-Stimulating Factor 2 Sargramostim sargramostim DRG-0012 Leukine Prokine rhu GM-CFS |
|
| Definitions |
A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1492 |
|
| Accepted_Therapeutic_Use_For |
Melanoma; Neutropenia-chemotherapy induced
|
|
| ALT_DEFINITION |
A substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets. It is a cytokine that is a type of hematopoietic (blood-forming) agent.
|
|
| CAS_Registry |
123774-72-1
|
|
| code |
C1492
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc
|
|
| DEFINITION |
A recombinant therapeutic agent chemically identical to endogenous human GM-CSF except a leucine substitution in position 23. Binding to specific cell surface receptors, sargramostim modulates the proliferation and differentiation of a variety of hematopoietic progenitor cells with some specificity towards stimulation of leukocyte production and may reverse treatment-induced neutropenias. This agent also promotes antigen presentation, up-regulates antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function; it may also augment host antitumoral immunity.
|
|
| Display_Name |
Sargramostim
|
|
| FDA_UNII_Code |
5TAA004E22
|
|
| FULL_SYN |
Sagramostim Sargramostatin SARGRAMOSTIM 23-L-Leucinecolony-Stimulating Factor 2 Sargramostim sargramostim DRG-0012 Leukine Prokine rhu GM-CFS
|
|
| Is_Value_For_GDC_Property | ||
| label |
Sargramostim
|
|
| Legacy Concept Name |
Sargramostim
|
|
| Maps_To |
Sargramostim
|
|
| NCI_Drug_Dictionary_ID |
40566
|
|
| PDQ_Closed_Trial_Search_ID |
40566
|
|
| PDQ_Open_Trial_Search_ID |
40566
|
|
| Preferred_Name |
Sargramostim
|
|
| prefixIRI |
Thesaurus:C1492
|
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance
|
|
| UMLS_CUI |
C0216231
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |